Diabetes and coronary stent implantation: Experience from a reference center in interventional cardiology;Diabetes e implante de stents coronarianos: Experiência de um centro de referência em cardiologia intervencionista

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 1, 2006, Pages 38-45

  Schaan, Beatriz D ^a,b   Quadros, Alexandre ^a   Sarmento Leite, Rogério ^a   Gottschall, Carlos A M ^a  

^a INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^b Unidade de Pesquisa   (Brazil)

Author keywords

Diabetes mellitus; Ischemic cardiac disease; Myocardial revascularization; Percutaneous coronary angioplasty

Indexed keywords

EID: 33646744351     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302006000100006     Document Type: Article

References (37)

1. Nesto R, Libby P. Diabetes mellitus and the cardiovascular system. In: Brauwald E, Zipes D, Libby P, eds. Heart disease. A textbook of cardiovascular medicine. Philadelphia: WB Saunders, 2001. p.2133.
2. Schaan BD, Harzheim E, Gus I. Cardiac risk profile in diabetes mellitus and impaired fasting glycemia. Rev Saúde Pública 2004;38(4):529-36.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
4. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: A report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004;109(4):476-80.
5. Brooks RC, Detre KM. Clinical trials of revascularization therapy in diabetes. Curr Opin cardiol 2000;15:287-92.
6. Aronson D, Bloogarden Z, Rayfild EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528-35.
7. Scott-Burden T, Vanhoutte PM. The endothelium as a regulator of vascular smooth muscle proliferation. Circulation 1993;87(suppl. 5):51-5.
8. Kanzaki T, Shinomiya M, Ueda S, Morisaki N, Saito Y, Yoshida S. Enhanced arterial intimal thickening after balloon catheter injury in diabetic animals accompanied by PDGF B-receptor over-expression. Eur J Clin Invest 1994;24:377-81.
9. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-1 and platelet derived grow factors-BB induce direct migration of human smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Ivest 1994;93:1266-74.
10. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
11. Carrozza JP, Kuntz RE, Fishman RF, Bain DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993;118:344-9.
12. Lau KW, Ding ZP, Johan A, Lim YL. Midterm angiographic outcome of single-vessel intracoronary stent placement in diabetic versus nondiabetic patients: A matched comparative study. Am Heart J 1998;136:150-5.
13. Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bucher TA, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: A serial intravascular ultrasound study. Circulation 1997;95(6):1366-9.
14. Mehran R, Dangas GD, Kobayashi Y, et al. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol 2004;43:1355-7.
15. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-73.
16. Mattos LA, Grines CL, Sousa JE, Sousa AG, Stone GW, Cox D, et al. One-year follow-up after primary coronary intervention for acute myocardial infarction in diabetic patients. A substudy of the STENT PAMI trial. Arq Bras Cardiol 2001;77:549-61.
17. Bayerl DM, Siqueira E, Moscoso I, Santos E, Maeda A, Bittencourt O, et al. Coronary stent implantation in diabetic versus nondiabetic patients. Early and late outcomes. Arq Bras Cardiol 2000;75:365-8.
18. Quadros AS, Gottschall CAM, Sarmento-Leite R, Gus M, Wainstein R, Bussmann A. Predictive factors of complications after coronary stent implantation. Arq Bras Cardiol 2003;80(5):538-43.
19. Holmes DR Jr, Hirshfeld J Jr, Faxon D, Vlietstra RE, Jacobs A, King SB 3rd. ACC expert consensus document on coronary artery stents. Document of the American College of Cardiology. J Am Coll Cardiol 1998;32:1471-82.
20. The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings. N Engl J Med 1985;312:932-6.
21. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation 1990;82:1193-202.
22. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998;32:584-9.
23. Van Belle E, Perie M, Braune D, Chmait A, Meurice T, Abolmaali K, et al. Effects of coronary stenting on vessel potency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol 2002;40:410-7.
24. The Bari Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 1997;96:1761-9.
25. Schuhlen H, Kastrati A, Dirschinger J, Hausleiter J, Elezi S, Wehinger A, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998;98:104-11.
26. Quadros AS, Sarmento-Leite R, Gottschall CAM. Predictive score for target vessel revascularization after stenting. Eur Heart J 2004;25(suppl.):313.
27. Gottschall CAM, Miller V, Yordi LM, Cardoso CR, Rodrigues L. Detection of restenosis after percutaneous transluminal coronary angioplasty by an angiographic score. J Invasive Cardiol 1998;10:1-11.
28. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-36.
29. Akiyama T, Moussa I, Reimers B, Ferraro M, Kobayashi Y, Blengino S, et al. Angiographic and clinical outcome following coronary stenting of small vessels: A comparison with coronary stenting of large vessels. J Am Coll Cardiol 1998;32:1610-8.
30. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998;98:1875-80.
31. Detre KM, Guo P, Holubkov R, Califf RM, Sopko G, Bach R, et al. Coronary revascularization in diabetic patients: A comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999;99:633-40.
32. Quadros AS, Sarmento-Leite R, Gottschall CAM. Stents farmacoló gicos: análise crítica das indicações e resultados dos estudos internacionais. Rev Bras Cardiol Invasiva 2005;no prelo.
33. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-8.
34. Quadros AS, Sarmento-Leite R, Gottschall CAM. Costeffectiveness of drug-eluting stents in large vessels: A tough limit to cross. Am J Cardiol 2003;92(suppl. 6A):26L.
35. Sobel BE, Frye R, Detre KM. Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 2003;107(4):636-42.
36. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004;43(1):8-14.
37. Abizaid A, Abizaid AS, Mehran R, Dengas G, Morice M, Schofer J, et al. Sirolimus-eluting stents in diabetic patients: Integrated analysis of six multicenter trials. J Am Coll Cardiol 2005;45(suppl.):50A.